TORONTO, ON / ACCESSWIRE / July 9, 2020 / Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) ("Predictmedix" or the "Company") an Artificial Intelligence company developing novel technologies for health and safety within workplaces and for healthcare, and launching its COVID-19 detection screening solution in advance of screening solutions for impairment and mental illness, will be presenting at "Wall Street Reporter's "Next Super Stock" livestream conference on Friday July 10, 2020.
Dr. Rahul Kushwah, COO of Predictmedix will share an overview of their three detection screening solutions, their recent acquisition of a remote patient monitoring platform to "close the loop" between detection and remote treatment monitoring, as well as new distribution partners in North America, UK and Caribbean.
Predictmedix presentation will take place at 1 pm EST on Friday, July 10, 2020.
Following the 20-minute presentation, Dr. Kushwah will take questions from the audience.
To sign up for the event, https://www.wallstreetreporter.com/next-superstock-online-investor-conference/
Recent company highlights include:
- Launch of COVID-19 test study with Max Healthcare, part of a multibillion-dollar healthcare conglomerate
- Launch of Mental Illness study with Max Healthcare in collaboration with Dr. Banerji, one of Asia Pacific's foremost neurologists
- Sales agreements signed with Juiceworks Exhibits, whose clients include Fortune 500 companies and the world's best-known brands, Caribbean Digital Media Academy technology integrator for corporations and government, and Taurus Medical who manufacture and market over 1,500 products for the diagnosis, treatment and monitoring of respiratory conditions in the UK.
- Incorporation of Predictmedix solutions within the tech suite to be offered by Tech Mahindra, a multibillion revenue conglomerate ranked among the world's top 15 IT companies
- Appointment of Mr. Kapil Raval, Director of AI, Business Development Microsoft, as chair our advisory board and to assist with business development
- Appointment of Mr. Prabhakar Srivastava, senior healthcare executive who has worked with some of the largest global healthcare conglomerates and has been an advisor to governments of African and Asian countries, will play a key role in business development for those regions
- Acquisition of Mobile Wellbeing Remote Patient Monitoring Telehealth Platform
- Filing of two patents for Remote Patient Monitoring Telehealth Platform in addition to the two patents for COVID-19 and Impairment detection screening
Disclaimer: "The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time."
About "Next Super Stock Live!" conference:
Wall Street Reporter's "NEXT SUPER STOCK Live!" conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. To view the conference visit: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/
About Predictmedix Inc.
Predictmedix Inc. is an artificial intelligence ("AI") company developing disruptive tools for impairment testing and healthcare. It is intended that the Company's cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.
The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious diseases such as influenza and coronaviruses (COVID-19). Our current partners along with advisory board members have played a key role in gathering data pertaining to COVID-19, which has allowed us to develop a predictive mass screening tool for COVID-19. The technology is for mass screening and is to be used to predict and identify individuals who have the highest likelihood of being infected with COVID-19.
Additionally, psychiatric disorders such as depression, dementia and Alzheimer's disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer's disease. To find out more visit us at www.predictmedix.com
For further information, please contact:
Dr. Rahul Kushwah, Chief Operating Officer
Tel: 647 889-6916
Email: [email protected]
Caution Regarding Forward-Looking Information:
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
SOURCE: PredictMedix Inc.